Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $7.50

Terns Pharmaceuticals (NASDAQ:TERN) had its target price boosted by HC Wainwright from $5.50 to $7.50 in a research note published on Wednesday morning,Benzinga reports. They currently have a neutral rating on the stock. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.17) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.58) EPS and FY2028 earnings at ($0.64) EPS.

A number of other research analysts also recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $26.00 price objective (up from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. JMP Securities upped their target price on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 10th. Finally, Oppenheimer assumed coverage on shares of Terns Pharmaceuticals in a research report on Thursday, October 31st. They set an “outperform” rating and a $82.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.25.

Terns Pharmaceuticals Trading Down 5.8 %

Terns Pharmaceuticals stock opened at $6.17 on Wednesday. Terns Pharmaceuticals has a 1-year low of $3.59 and a 1-year high of $11.40. The firm has a market cap of $524.07 million, a P/E ratio of -5.23 and a beta of -0.32. The firm has a 50-day moving average of $8.03 and a 200-day moving average of $7.46.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, Director Jill M. Quigley sold 17,235 shares of Terns Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $10.00, for a total value of $172,350.00. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $150,000. The trade was a 53.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark J. Vignola sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the transaction, the chief financial officer now owns 91,940 shares in the company, valued at approximately $1,011,340. This trade represents a 9.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.10% of the stock is currently owned by insiders.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of TERN. Point72 Asset Management L.P. lifted its holdings in Terns Pharmaceuticals by 0.6% during the third quarter. Point72 Asset Management L.P. now owns 2,707,515 shares of the company’s stock valued at $22,581,000 after purchasing an additional 17,139 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Terns Pharmaceuticals by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,199,006 shares of the company’s stock worth $14,425,000 after buying an additional 11,535 shares during the period. Janus Henderson Group PLC boosted its holdings in Terns Pharmaceuticals by 40.6% in the 1st quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock worth $13,131,000 after buying an additional 578,500 shares during the period. Bellevue Group AG bought a new stake in Terns Pharmaceuticals during the third quarter valued at about $8,691,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Terns Pharmaceuticals by 127.9% in the first quarter. Russell Investments Group Ltd. now owns 632,965 shares of the company’s stock valued at $4,152,000 after acquiring an additional 355,224 shares in the last quarter. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.